Vasculitis Pipeline Insights Report 2022: Comprehensive Insights about 40+ Companies and 40+ Pipeline Drugs – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Vasculitis – Pipeline Insight, 2022” clinical trials has been added to ResearchAndMarkets.com’s offering.

The “Vasculitis – Pipeline Insight, 2022” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Vasculitis pipeline landscape.

The assessment part of the report embraces, in depth Vasculitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Vasculitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

Companies and academics are working to assess challenges and seek opportunities that could influence Vasculitis R&D. The therapies under development are focused on novel approaches to treat/improve Vasculitis.

Vasculitis Emerging Drugs Chapters

This segment of the Vasculitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Vasculitis Emerging Drugs

Secukinumab: Novartis

Secukinumab inhibits interleukin (IL)-17A, and has shown significant benefits in conditions mediated by this cytokine such as plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis. There also are experimental and preclinical data that point towards a role for IL-17A in the pathogenesis of giant cell arteritis, and therefore IL-17A inhibition by blocking vascular inflammation is potentially a new therapeutic target.

Secukinumab showed promise as a steroid-sparing agent in giant cell arteritis. Currently the drug is in Phase 3 stage of evaluation for the treatment Giant Cell Arteritis (GCA). Giant cell arteritis (GCA) is the most common form of vasculitis that occurs in adults.

Belimumab (Benlysta): GlaxoSmithKline

Benlysta, a BLyS-specific inhibitor, is a human monoclonal antibody that binds to soluble BLyS. Benlysta does not bind B cells directly. By binding BLyS, Benlysta inhibits the survival of B cells, including autoreactive B cells, and reduces the differentiation of B cells into immunoglobulin-producing plasma cells. The drug is in phase 3 of clinical trials for the treatment of Anti-neutrophil cytoplasmic antibody-associated vasculitis.

Vilobelimab: InflaRx

InflaRx’s lead drug candidate, vilobelimab, is a first-in-class monoclonal antibody targeting the complement activation product C5a and is currently in clinical development for several indications, including ANCA-Associated Vasculitis (AAV), a rare, life-threatening autoimmune disease. Based on the eminent role of C5a in the progression of inflammation in this life-threatening disease, InflaRx is currently conducting clinical testing in AAV.

AMB-301: Ambulero

AMB-301 is a promising gene therapy candidate for enhancing blood vessel formation, restoring tissue integrity, and eliminating the need for amputation as a treatment. It is a first-in-class gene therapy vector encoding a cell adhesion molecule, E-selectin.

More than a decade of research in animal models with vascular disease suggests that providing E-selectin to damaged blood vessels and surrounding tissue promotes therapeutic angiogenesis, supports robust tissue regeneration, and improved limb function.

Vasculitis: Therapeutic Assessment

This segment of the report provides insights about the different Vasculitis drugs segregated based on the following parameters that define the scope of the report, such as:

Major Players in Vasculitis

There are approx. 40+ key companies which are developing the therapies for Vasculitis. The companies which have their Vasculitis drug candidates in the most advanced stage, i.e. phase III include, Novartis.

Phases

The report covers around 40+ products under different phases of clinical development like:

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of: Pre-clinical and Discovery stage candidates, Discontinued & Inactive candidates, and Route of Administration.

Vasculitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
• Molecule Type

Products have been categorized under various Molecule types such as:

• Oligonucleotide
• Peptide
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Vasculitis: Pipeline Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Vasculitis therapeutic drugs key players involved in developing key drugs.

Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Vasculitis drugs.

Vasculitis Report Insights

• Vasculitis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Vasculitis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Players

• Novartis
• AbbVie
• InflaRx
• Janssen Biotech
• Beijing Defengrei Biotechnology
• Ambulero
• Visterra
• ChemoCentryx
• GlaxoSmithKline
• Roche
• CytoDyn
• Toleranzia
• Citryll
• Levolta

Key Products

• Belimumab (Benlysta)
• Upadacitinib
• Vilobelimab (IFX-1)
• BDB 1
• AMB 301
• Guselkumab
• Secukinumab

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/vtakig

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900